Product category |
|
Therapeutic indication |
|
Dosing |
|
Efficacy |
|
Key features |
|
Challenges |
|
Status |
- WHO prequalification obtained in April 2021
- 2nd taste-masked and dispersible SPAQ formulation prequalified by WHO
- Registered in 6 countries; ongoing in 5 other countries
- 18 million treatments delivered in 2021
|
Next milestone |
- Extension of the recommendation for children up to their 10th birthday
- Validation of the dose and development of a specific packaging for children from 5 years old up until their 10th birthday
- Exploration of expanded SMC coverage by adding a fifth monthly round of treatment in areas with longer seasonal transmission
- Confirmation of potential efficacy and adoption in areas outside of the Sahel region
|
MMV Project Director |
|